<DOC>
	<DOCNO>NCT00637065</DOCNO>
	<brief_summary>Over time , patient fibrosing interstitial lung disease ( ILD ) develop high lung blood pressure ( pulmonary hypertension ) , associate poor prognosis survival . It think development PH contribute deterioration death patient ILD . Endothelin-1 ( ET1 ) substance contribute development PH ILD . Bosentan drug block action ET-1 binding receptor . Bosentan clearly benefit patient PH unknown cause , relate disease ( heart condition , HIV ) alone combination treatment . In patient fibrosing lung disease PH , control treatment study . Clearly important evaluate effectiveness bosentan patient . This study aim determine ability bosentan reduce high blood pressure lung ( pulmonary hypertension ) patient scar ( fibrosing ) lung disease . It placebo-controlled double blind study 16 week ( propose follow patient 16 week open-label phase bosentan therapy ) .</brief_summary>
	<brief_title>Bosentan Pulmonary Hypertension Interstitial Lung Disease Treatment Study</brief_title>
	<detailed_description>• Purpose : High blood pressure lung pulmonary hypertension ( PH ) common complication fibrosing ( interstitial , ILD ) lung disease . When present , associate markedly reduced prognosis survival . Endothelin-1 ( ET-1 ) over-expressed patient PH ILD , think play role development condition . Bosentan block action ET-1 , show beneficial patient PH unknown cause , related condition ( heart condition , connective-tissue disease , HIV ) . It important establish whether bosentan treatment also benefit patient PH ILD . This study address effectiveness bosentan context PH ILD . • Objective : To examine ability bosentan reduce high blood pressure lungs patient fibrosing lung disease pulmonary hypertension . • Design : This multi-centre , randomise , double-blinded , placebo-controlled study look effect bosentan patient fibrotic lung disease PH . • Methodology : Patients recruit outpatient ILD PH clinical service consent prior enter study . We propose study 48 patient 16 week period . Patients include study fibrosing lung disease ( specifically : idiopathic pulmonary fibrosis idiopathic fibrosing non-specific pneumonitis ) PH determine measurement right heart catheter ( mean pulmonary artery pressure &gt; =25mmHg , pulmonary capillary wedge pressure = &lt; 15mmHg ) . Patients enter 2 week screen period full medical history examination . If already clinically important investigation ( echocardiogram , cardiac MRI , overnight oximetry ) within previous 6 week CT scan within last 3 month , perform . The patient baseline 6 minute walk test , ECG ( heart trace ) , blood test pulmonary blood flow study ( breath test ) lung function test ( breathe test ) complete quality life questionnaire . The patient randomise bosentan placebo ( 2:1 ) baseline visit . Patients follow every 4 week physical examination , blood test . At week 16 , initial investigation ( include right heart catheter , lung function , pulmonary blood flow , 6-minute walk , blood test , echocardiogram cardiac MRI complete quality life questionnaire ) repeat . Patients offer treatment open-labelled bosentan therapy result trial become available maximum 2 year .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>1 . Patients &gt; =18yrs , &lt; 80yrs 2 . Patients idiopathic pulmonary fibrosis ( IPF ) idiopathic fibrotic nonspecific interstitial pneumonitis ( NSIP ) confirm respiratory physician accord ATS/ERS criterion . 3 . Patients pulmonary hypertension right heart catheter ( mean pulmonary arterial pressure &gt; =25mmHg pulmonary artery occlusion pressure , leave atrial pressure leave ventricular enddiastolic pressure &lt; 15mmHg ) . 4 . Patients provide write informed consent . 1 . Patients &lt; 18 , &gt; 80yrs . 2 . Patients unstable disease , acute exacerbation underlie fibrotic lung disease . 3 . Patients significant organ comorbidity include hepatic renal impairment . 4 . Patients systolic BP &lt; 85mmHg 5 . Patients condition may affect ability perform 6minute walk test . 6 . Patients unable provide inform consent comply patient protocol . 7 . Patients receive excluded medication ( include : epoprostenol , prostacyclin analogue , phosphodiesterase inhibitor , endothelin receptor antagonist , drug potential interaction bosentan glibenclamide , fluconazole , cyclosporin A , tacrolimus , investigational agent ) . 8 . Patients plan surgical intervention study period . 9 . Pregnant patient woman childbearing age , use reliable contraceptive method . 10 . Patients clinically overt ischaemic heart disease . 11 . Patients predominant emphysema high resolution CT scan ( emphysema great extent interstitial change ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Pulmonary hypertension</keyword>
	<keyword>Interstitial lung disease</keyword>
	<keyword>Idiopathic pulmonary fibrosis</keyword>
	<keyword>Nonspecific interstitial pneumonia</keyword>
	<keyword>Bosentan</keyword>
	<keyword>Endothelin receptor antagonist</keyword>
	<keyword>Pulmonary vascular resistance</keyword>
</DOC>